Biomet became aware of violations in October 2013 and conducted an internal investigation. The executives and employees involved in the violations were disciplined or terminated and the company discussed the situation with the Securities and Exchange Commission in April last year.
The investigation is ongoing, but the DOJ could bring further actions against Biomet if the DOJ determines the company’s activities breached the deferred prosecution agreement. The agreement is extended for another year.
More articles on orthopedic devices:
Greatbatch short interest drops by 8.5% — 4 things to know
Amedica to present CASCADE clinical results
Spine device stock report: 5 key companies
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
